Clinical trials
Follow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
HRS-4642 + adebrelimab + nab-paclitaxel + gemcitabine
- Development stage
- Phase 2
- Lead developer
- Shanghai Hengrui Pharmaceutical Co., Ltd.
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics, Small Molecules, Nanoparticles → Drug Delivery Systems
- Administration
- Intravenous
01
Overview
This combination therapy regimen is being developed by Shanghai Hengrui Pharmaceutical Co., Ltd. for the treatment of pancreatic adenocarcinoma, specifically targeting patients with KRAS G12D mutations. The regimen integrates four distinct therapeutic agents: HRS-4642, a highly selective small molecule inhibitor of the KRAS G12D mutation; adebrelimab (also known as SHR-1316), a humanized IgG4 monoclonal antibody that acts as a PD-L1 checkpoint inhibitor; and the standard chemotherapy doublet of nab-paclitaxel (albumin-bound paclitaxel) and gemcitabine. By combining targeted inhibition of a primary oncogenic driver with immunotherapy and cytotoxic chemotherapy, the regimen aims to achieve synergistic anti-tumor activity. It is currently under evaluation in Phase 1b/2 clinical trials for locally advanced or metastatic pancreatic cancer.
- Brand names
- Airuili
- Other names
- HRS-4642 + SHR-1316 + nab-paclitaxel + gemcitabineHRS-4642 + adebrelimab + albumin-bound paclitaxel + gemcitabine
02
Targets
KRASG12D (Kirsten rat sarcoma viral oncogene homolog (KRAS) G12D mutant)CD274 (Programmed cell death protein 1 ligand 1)RNR (Ribonucleotide reductase)TUBB (Tubulin (alpha and beta subunits))DNA
Beyond the preview
Go deeper on HRS-4642 + adebrelimab + nab-paclitaxel + gemcitabine.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Explore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Trace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Explore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Compare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Connect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on HRS-4642 + adebrelimab + nab-paclitaxel + gemcitabine.